Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial.
BACKGROUND
Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. This phase II trial evaluated the efficacy and toxicity of docetaxel plus cisplatin, as salvage chemotherapy in patients with MBC resistant to prior anthracyclines.


METHODS
Patients with MBC that had progressed after at least one prior chemotherapy regimen containing anthracyclines received docetaxel 75 mg/m2 followed by cisplatin 60 mg/m2 every 3 weeks for a maximum of 6 cycles or until disease progression.


RESULTS
Between Jan 2000 and May 2002, 24 patients with tumors primary resistant and 15 with secondary resistant disease were accrued. All 39 patients were evaluable for safety and 36 for efficacy. The objective response rate was 31% (95% CI, 16-45%) with 3 complete responses. The median time to disease progression was 7 months, and the median overall survival was 23 months (median follow-up of 41 months). Neutropenia was the most frequently observed severe hematologic toxicity (39% of patients), whereas asthenia and nausea were the most common non-hematologic toxicities. No treatment-related death was observed.


CONCLUSIONS
In conclusion, we found docetaxel plus cisplatin to be an active and safe chemotherapy regimen for patients with MBC resistant to anthracyclines.
Park
Se Hoon
SH
Division of Hematology and Oncology, Internal Medicine, Gachon Medical School Gil Medical Center, Incheon 405-760, Korea. hematoma@ghil.com
Cho
Eun Kyung
EK
Bang
Soo-Mee
SM
Shin
Dong Bok
DB
Lee
Jae Hoon
JH
Lee
Young Don
YD
D000328:Adult; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D018450:Disease Progression; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D016879:Salvage Therapy; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000556:secondary*; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage
D018943:Anthracyclines; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
Biometrics. 1982 Mar;38(1):143-51
7082756
Breast Cancer Res Treat. 2003;79 Suppl 1:S11-8
12868801
N Engl J Med. 1994 May 5;330(18):1253-9
8080512
Anticancer Drugs. 1995 Jun;6(3):339-55, 363-8
7670132
J Clin Oncol. 1995 Dec;13(12):2879-85
8523050
J Clin Oncol. 1995 Dec;13(12):2886-94
8523051
J Clin Oncol. 1996 Apr;14(4):1185-91
8648373
J Clin Oncol. 1997 Mar;15(3):1071-9
9060547
J Clin Oncol. 1998 Oct;16(10):3362-8
9779713
Ann Oncol. 1999 Jan;10(1):119-22
10076732
Semin Oncol. 1999 Feb;26(1 Suppl 3):5-9
10203264
Anticancer Res. 1999 Jan-Feb;19(1A):291-9
10226557
J Clin Oncol. 1999 May;17(5):1413-24
10334526
Semin Oncol. 1999 Jun;26(3 Suppl 11):13-8
10458205
Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37
11301372
J Clin Oncol. 1999 Jul;17(7):2069-80
10561260
J Clin Oncol. 1999 Sep;17(9):2971-94
10561376
Eur J Cancer. 1999 Aug;35(8):1194-201
10615229
Cancer. 2000 Jan 1;88(1):124-31
10618614
Ann Oncol. 1999 Nov;10(11):1385-8
10631471
Ann Oncol. 1999 Dec;10(12):1457-60
10643536
Ann Oncol. 2000 Mar;11(3):301-6
10811496
J Clin Oncol. 2001 Jan 15;19(2):336-42
11208824
N Engl J Med. 2001 Mar 15;344(11):783-92
11248153
Jpn J Cancer Res. 2002 May;93(5):574-81
12036454
Oncol Rep. 2002 Nov-Dec;9(6):1345-9
12375046
Oncologist. 2002;7 Suppl 6:4-12
12454314
Oncology. 2003;64(3):207-12
12697959
Semin Oncol. 1989 Aug;16(4 Suppl 6):110-5
2669132